title: Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.
abstract: We retrospectively analyzed the outcome of high-risk patients with non-small cell lung cancer (NSCLC) treated with nedaplatin (NP) and irinotecan (CPT) combination chemotherapy. Between July 2002 and January 2006, 31 NSCLC patients with multiple high-risk factors were treated with NP at 50 mg/m2 and CPT at 50 mg/m2 on days 1 and 8 every 4 weeks. Among them, the patients had a total of 85 risk factors, including poor performance status (2 or 3) in 27, cardiac or pulmonary failure in 15, symptomatic bone or brain metastasis in 9, and advanced age (> or = 75 years) in 8, as well as other factors. A total of 83 courses of the chemotherapy were administered and 24 patients were able to receive 2 to 4 courses. With regard to toxicities, 7 (8.4%) and 11 courses (13%) were associated with grade 4 neutropenia and grade 3 febrile neutropenia, respectively. One patient suffered acute myocardial infarction. Each of the toxicities was controllable and there were no treatment-related deaths. One patient achieved CR, 13 achieved PR, 14 SD and 3 PD, and the overall response rate was 45.2%. Of 26 patients with stage IIIB or IV, the median survival time was 232 days, the 1-survival rate was 38.5%, and 3 patients survived for more than 3 years. In conclusion, chemotherapy with NP and CPT appears to be safe and highly effective for high-risk patients with NSCLC.
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. foshita@kcch.jp
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Oshita
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Saito
authors.forename: Kouzo
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002166:Camptothecin